Advancing a stem cell–based therapeutic for ALS

With promising early-phase data in hand, BrainStorm Cell Therapeutics is now putting its stem cell treatment for amyotrophic lateral sclerosis (ALS) through the rigors of phase 2 testing. To download the full article, please sign in.

Page of
Go to the profile of BrainStorm Cell Therapeutics

BrainStorm Cell Therapeutics

BrainStorm Cell Therapeutics (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).

Comments are disabled